Skip to content

Study · Randomized controlled trial · n = 27 · 2017

9 results

The effect of liraglutide on renal function: A randomized clinical trial.

von Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen TW, Rossing P

Diabetes, obesity & metabolism21 Nov 2016Cited by 86 (Europe PMC)

PMID27753201 (opens in a new tab)DOI10.1111/dom.12808 (opens in a new tab)PepBankPUB-27753201
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and albuminuria, liraglutide reduced the urinary albumin excretion rate by 32% versus placebo.

    In plain wordsIn adults with type 2 diabetes and albuminuria, liraglutide reduced urinary albumin loss more than placebo.

    Peptide
    Liraglutide
    Outcome
    Decrease24-h urinary albumin excretion rate
    Study

    n = 27

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Measurements

    UAER reduction
    32%
    liraglutide vs placebo

    Source sentences

    Summary
    Furthermore, liraglutide reduced UAER by 32 (95% CI: 7; 50)% ( P = .017) compared with placebo.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and albuminuria, liraglutide reduced HbA1c by 8 mmol/mol versus placebo.

    In plain wordsIn adults with type 2 diabetes and albuminuria, liraglutide lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Measurements

    HbA1c reduction
    −8 mmol/mol
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide reduced HbA1c by 8 (95% CI: 5; 11) mmol/mol (P < .001)
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and albuminuria, liraglutide reduced body weight by 1.8 kg versus placebo.

    In plain wordsIn adults with type 2 diabetes and albuminuria, liraglutide reduced body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Measurements

    Weight reduction
    −1.8 kg
    liraglutide vs placebo

    Source sentences

    Summary
    and weight by 1.8 (95% CI: 0.2; 3.4) kg (P = .032) compared to placebo
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and albuminuria, the change in measured GFR with liraglutide was not statistically significant (P = .15).

    In plain wordsIn adults with type 2 diabetes and albuminuria, liraglutide did not significantly change measured kidney filtration.

    Peptide
    Liraglutide
    Outcome
    No significant changeMeasured GFR change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Measurements

    mGFR change
    −5 mL/min/1.73 m2
    liraglutide vs placebo

    Source sentences

    Summary
    The change in mGFR was -5 (95% CI: -11; 2) mL/min/1.73 m2 ( P = .15)
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and albuminuria, the change in 24-h systolic blood pressure with liraglutide was not statistically significant (P = .07).

    In plain wordsIn adults with type 2 diabetes and albuminuria, liraglutide did not significantly change 24-hour systolic blood pressure.

    Peptide
    Liraglutide
    Outcome
    No significant change24-h systolic blood pressure change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Measurements

    24-h systolic blood pressure change
    −5 mm Hg
    liraglutide vs placebo

    Source sentences

    Summary
    and change in 24-h systolic blood pressure was -5 (95% CI: -10; 0) mm Hg ( P = .07).
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.
  6. 06HumanRandomized controlled trialOther

    In adults with type 2 diabetes and albuminuria treated with liraglutide, change in UAER was associated with change in 24-h systolic blood pressure (P = .025).

    In plain wordsIn adults with type 2 diabetes on liraglutide, a bigger fall in urinary albumin loss was linked to a bigger fall in systolic blood pressure.

    Peptide
    Liraglutide
    Outcome
    Not applicableAssociation of UAER change with systolic blood pressure change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In multivariate regression models, change in UAER was associated with change in 24-h systolic blood pressure ( P = .025)
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.
  7. 07HumanRandomized controlled trialOther

    In adults with type 2 diabetes and albuminuria treated with liraglutide, change in UAER was not associated with change in HbA1c (P >= .14).

    In plain wordsIn adults with type 2 diabetes on liraglutide, the change in urinary albumin loss was not linked to the change in HbA1c.

    Peptide
    Liraglutide
    Outcome
    No significant changeAssociation of UAER change with HbA1c change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In multivariate regression models, change in UAER was associated with change in 24-h systolic blood pressure ( P = .025) but not with change in HbA1c, weight or mGFR ( P ≥ .14), overall model R 2 = .39.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.
  8. 08HumanRandomized controlled trialOther

    In adults with type 2 diabetes and albuminuria treated with liraglutide, change in UAER was not associated with change in weight (P >= .14).

    In plain wordsIn adults with type 2 diabetes on liraglutide, the change in urinary albumin loss was not linked to the change in weight.

    Peptide
    Liraglutide
    Outcome
    No significant changeAssociation of UAER change with weight change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In multivariate regression models, change in UAER was associated with change in 24-h systolic blood pressure ( P = .025) but not with change in HbA1c, weight or mGFR ( P ≥ .14), overall model R 2 = .39.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.
  9. 09HumanRandomized controlled trialOther

    In adults with type 2 diabetes and albuminuria treated with liraglutide, change in UAER was not associated with change in mGFR (P >= .14).

    In plain wordsIn adults with type 2 diabetes on liraglutide, the change in urinary albumin loss was not linked to the change in kidney filtration.

    Peptide
    Liraglutide
    Outcome
    No significant changeAssociation of UAER change with mGFR change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.8 mg/d · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In multivariate regression models, change in UAER was associated with change in 24-h systolic blood pressure ( P = .025) but not with change in HbA1c, weight or mGFR ( P ≥ .14), overall model R 2 = .39.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 .
    Summary · context
    Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02545738

Antiproteinuric Effects of Liraglutide Treatment

Steno Diabetes Center Copenhagenn = 32Apr 2015 to May 2016

Diabetic Kidney Disease

Trial pageClinicalTrials.govUpdated 10 Aug 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.